Physician profile
Eric H Lieberman
NPI 1437184322
$2,783.15
in general payments reported to CMS, 2019-2025
12 companies · $555 in 2025
The $555 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,213 · 2020: $148 · 2021: $31.87 · 2022: $210 · 2023: $291 · 2024: $334 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $802.05 | 2019-2020 | |
| Edwards Lifesciences Corporation | $348.45 | 2019-2025 | |
| Heartflow, INC. | $315.62 | 2019-2023 | Ffrct |
| Abiomed | $294.27 | 2023-2025 | Impella |
| Boston Scientific Corporation | $293.00 | 2019-2022 | |
| Cleerly, INC. | $170.90 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Medtronic, INC. | $140.45 | 2024 | Corevalve Evolut R |
| Biosense Webster, INC. | $137.50 | 2022-2024 | Carto 3 |
| Medtronic Vascular, INC. | $118.14 | 2019 | |
| Atricure, INC. | $92.93 | 2024 | |
| Cook Medical LLC | $58.47 | 2019 | |
| Dova Pharmaceuticals | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lieberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.